top of page
Search

Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101

  • Writer: SBIJI Innovation
    SBIJI Innovation
  • Jan 29, 2021
  • 1 min read

Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer

 
 
 

Recent Posts

See All

Kommentarer


A Member firm of SBI Group, Japan

© 2020 SBI JI Innovation Advisory Ltd. All rights reserved

bottom of page